| AZ | EN | RU

STATISTICS


ASSESSMENT OF QUALITY OF LIFE AFTER RADIOACTIVE IODINE TREATMENT
Mammadova A.E.

DOI: 10.61775/2413-3302.v1i39.12

SUMMARY
This study aimed to evaluate the impact of radioactive iodine therapy on the quality of life in patients diagnosed with Graves’ disease and toxic adenoma. The findings suggest that radioactive iodine therapy positively influences not only hormonal stabilization but also psychosocial well-being. Specific tools like ThyPRO-39 are recommended for comprehensive clinical monitoring of patient outcomes post-treatment.
Keywords: Graves’ disease, toxic adenoma, quality-of-life indicator

REFERENCES
  1. Ajjan RA, Weetman AP, Dayan CM. Management of Graves’ disease: A review // Nature Reviews Endocrinology. 2021;17(11):724-736. doi: 10.1038/s41574-021-00563-2.
  2. Bednarczuk T, Brix TH, Schima W, Zettinig G, et al. 2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction // Eur Thyroid J. 2021 Jul;10(4):269-284. doi: 10.1159/000517175.
  3. El Fassi D, Brix TH. Quality of life following radioiodine therapy in hyperthyroid patients: What matters most? // Endocrine Connections. 2022;11(2):e210476. doi: 10.1530/EC-21-0476.
  4. Kanokwongnuwat W, Penpong N. Prospective study to evaluate radioactive iodine of 20 mCi vs 10-15 mCi in Graves’ disease // BMC Endocrine Disorders. 2024;24:54. doi: 10.1186/s12902-024-01588-3.
  5. Lee SY., Ryu MJ, Kim HJ. Impact of radioactive iodine therapy on the quality of life in patients with Graves’ disease // Frontiers in Endocrinology. 2021;12:678792. doi: 10.3389/fendo.2021.678792.
  6. Li Y, Yang T, Ju L, Wang Z. Quality of life and decision regret in patients with late-hypothyroidism after radioiodine treatment for Graves’ disease // Clinical Endocrinology (Oxford). 2024;100(1):87-95. doi: 10.1111/cen.14986.
  7. Mooij CF, Cheetham TD, Verburg FA, Eckstein A, et al. 2022 European Thyroid Association Guideline for the management of pediatric Graves' disease // Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073.
  8. Nilsson JN, Elovsson R, Thor D, Calissendorff J, et al. Radioiodine treatment outcome by dosimetric parameters and renal function in hyperthyroidism // Thyroid Research. 2022;15:8. doi: 10.1186/s13044-022-00126-4.
  9. Rigó A, Malkov K, Szabó A, Bognár VK, et al. Adaptation and validation of the Hungarian version of Thyroid-Related Patient-Reported Outcome-39 (ThyPro-39) questionnaire: testing factor structure, known-group validity with the comparison of quality of life in Hashimoto's thyroiditis and Graves' disease // J Patient Rep Outcomes. 2023 Jun 27;7(1):60. doi: 10.1186/s41687-023-00606-7.
  10. Taprogge J, Gape PM, Carnegie-Peake L. A systematic review and meta-analysis of the relationship between the radiation absorbed dose to the thyroid and response in patients treated with radioiodine for Graves’ disease // Thyroid. 2021;31(12):1829-1838. doi: 10.1089/thy.2021.0302.